Shanghai Chest Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1957-01-01
- Employees
- -
- Market Cap
- -
To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
Phase 2
- Conditions
- Non-small Cell Lung Cancer Stage IIIARadiotherapy
- Interventions
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT02977169
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer
Phase 2
- Conditions
- NSCLC
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT02975609
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
Phase 3
Terminated
- Conditions
- Non-small Cell Lung Cancer Stage IIIARadiotherapy
- Interventions
- Radiation: PORT-lastRadiation: PORT-first
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 132
- Registration Number
- NCT02974426
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Transbronchial Ablation for Peripheral Lung Tumor
Not Applicable
- Conditions
- Lung Cancer
- First Posted Date
- 2016-11-23
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT02972177
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial
Phase 2
- Conditions
- Lung Adenocarcinoma
- Interventions
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT02951637
Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma
Phase 2
- Conditions
- Pulmonary Large Cell Neuroendocrine Carcinoma
- Interventions
- First Posted Date
- 2016-10-25
- Last Posted Date
- 2016-10-25
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 118
- Registration Number
- NCT02943798
Precision Diagnosis for Intraoperative Frozen Section of Early Stage Lung Cancer
Not Applicable
- Conditions
- Lung Cancer
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 540
- Registration Number
- NCT02941003
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations
Phase 2
- Conditions
- SBRTGM-CSFNSCLC
- Interventions
- Drug: two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxelRadiation: SBRT concurrent with GM-CSF
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT02940990
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Phase II Study of Neo-adjuvant Chemoradiotherapy for Squamous Cell Esophageal Cancer
Phase 2
- Conditions
- ChemoradiationSurgeryEsophageal Cancer
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT02938195
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study
Phase 3
- Conditions
- Non-small-cell Lung Cancer
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2016-10-21
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT02938546